Tradestie Institutional Equity Comparison Engine

ALAB vs MCHPP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ALAB Overall Edge

ALAB Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Astera Labs, Inc. Common Stock (ALAB) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ALAB trades at 31.0x Forward P/E with 25.5% operating margin (+153.7% YoY revenue) versus MCHPP at N/M Forward P/E and 21.6% operating margin (+42.2% YoY). In options structure, ALAB sits in BREAKDOWN (31st %ile IV; Dealer Gamma Walls on Pro) against MCHPP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner ALAB
ALAB 31.0x vs MCHPP N/M Fwd P/E
Growth & Margin Winner ALAB
Op Margin 25.5% vs 21.6% ยท YoY +153.7% vs +42.2%
Momentum & Technical Winner ALAB
1Y +44.1% vs +0.8% ยท 52W Pos 28% vs 14%
Options & Structure Winner ALAB
BREAKDOWN (31st %ile IV) vs UNCLASSIFIED (N/A IV)
ALAB NASDAQ
Astera Labs, Inc. Common Stock
Semiconductors & Related Devices
$208.25
-6.12% 1D
Market Cap $39.8B
1M Return -27.14%
1Y Return +44.15%
Forward P/E 31.0x
Unified AI Score
53.4 / 100 HOLD
Tech 45.0 Fund 57.0 Flow 67.0 Mom 60.0
MCHPP NASDAQ
Microchip Technology Incorporated Depositary Shares Each Representing a 1/20th Interest in a Share of 7.50% Series A Mandatory Convertible Preferred Stock
Semiconductors & Related Devices
$52.64
-3.18% 1D
Market Cap N/A
1M Return -17.41%
1Y Return +0.8%
Forward P/E N/M
Unified AI Score
57.1 / 100 HOLD
Tech 74.0 Fund 61.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ALAB +44.15% MCHPP +0.8% Spread: +43.35 pp (ALAB Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ALAB TTM Op. Margin: 25.5% MCHPP TTM Op. Margin: 21.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ALAB vs MCHPP. Trailing 12-month operating profitability (ALAB 25.5% vs MCHPP 21.6%) and valuation multiples (ALAB 31.0x vs MCHPP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ALAB (8) vs MCHPP (2)
Institutional Metric ALAB MCHPP Criterion Row Winner
Market Capitalization Scale $39.8B N/A Larger Scale ALAB
Trailing P/E Ratio Valuation 90.0x N/M Lower Multiple ALAB
Forward P/E Ratio Valuation 31.0x N/M Lower Multiple ALAB
Revenue Growth (YoY) Growth +153.7% +42.2% Higher Growth ALAB
Operating Margin (TTM) Profitability 25.5% 21.6% Higher Margin ALAB
Net Profit Margin Profitability 29.6% 15.0% Higher Margin ALAB
Return on Equity (ROE) Capital Efficiency 28.2% 12.6% Higher ROE ALAB
52-Week Range Position Momentum 28% ($98โ€“$499) 14% ($47โ€“$88) Stronger Trend ALAB
Beta / 30D Volatility Risk Regime 4.24ฮฒ ยท 124% Vol 2.16ฮฒ ยท 65% Vol Lower Realized Risk MCHPP
Unified Institutional Score Composite Signal 53.4 / 100 (HOLD) 57.1 / 100 (HOLD) Higher Composite MCHPP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ALAB vs MCHPP Buy Guide
ALAB BREAKDOWN
103d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 31st %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ALAB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MCHPP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MCHPP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ALAB nor MCHPP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.